Fapon's Two-Pronged Attack on B-Cell Disease Redefines Biotech Strategy

SAN DIEGO, CA – June 19, 2026 – In the bustling halls of the BIO International Convention, where the future of medicine is debated and dealt, a strategic gambit is unfolding that warrants close attention. Fapon Group, a life sciences conglomerate with roots in diagnostics, is making a decisive and sophisticated play in the high-stakes arena of advanced therapeutics. Through its affiliates, Fapon Biopharma and MOTE Therapeutics, the company is showcasing not just a promising new drug, but an entire strategic framework designed to de-risk innovation while maximizing therapeutic impact. Their dual-platform B-cell immunotherapy franchise, which pairs a T-cell engager with an in vivo CAR-T therapy, is more than just novel science; it's a blueprint for building competitive advantage in the turbulent 2026 landscape.

A Dual-Platform, Dual-Targeting Gambit

The core of the strategy, being presented this week in San Diego, is a two-pronged assault on B-cell-mediated diseases, spanning both autoimmune conditions and oncology. The approach simultaneously targets two well-validated B-cell markers, CD19 and BCMA, but does so using two distinct and complementary technological platforms. This is not simply about having multiple shots on goal; it’s about creating a synergistic system where each component has the potential to succeed on its own or work in concert.

First is Fapon Biopharma’s T-cell engager (TCE), FPE024. This tri-specific molecule is engineered to act as a bridge, linking a patient's own T-cells directly to malignant or pathogenic B-cells expressing CD19 and BCMA, thereby triggering a targeted cell-killing process. The company’s proprietary VHH platform, which uses smaller, single-domain antibodies, is designed to overcome the manufacturing and therapeutic window limitations that have plagued earlier generations of multi-specific antibodies. The inclusion of human-cynomolgus cross-reactivity is a critical, and often overlooked, element that streamlines the path from preclinical animal models to human trials—a key factor in accelerating development timelines.

Complementing the TCE is MTX001 from MOTE Therapeutics, an in vivo CAR-T therapy. Traditional CAR-T therapy is a complex and costly ex vivo process requiring a patient's T-cells to be harvested, genetically engineered in a lab, and then re-infused. MOTE’s approach aims to bypass this entirely. By using its proprietary mobilize™ targeted lipid nanoparticle (tLNP) platform, the company can deliver the genetic instructions for building the CAR directly to T-cells inside the patient’s body. This “off-the-shelf” potential represents a paradigm shift, promising greater accessibility, convenience, and scalability. The platform's ability to largely avoid the liver—a common destination for LNPs that limits their utility—and target specific cells outside it is the key innovation that could unlock the full potential of RNA therapeutics.

This dual-platform strategy is a masterclass in managing risk. By advancing both a biologic (the TCE) and a gene therapy (the in vivo CAR-T) for the same targets, Fapon Group is hedging against the inherent scientific and regulatory uncertainties of each modality. It creates optionality, allowing the company to pivot based on clinical data, patient populations, and the evolving commercial landscape.

Recalibrating the Frontiers of Gene Delivery

While Fapon Biopharma brings established biologics expertise, MOTE Therapeutics represents the group's forward-looking investment in next-generation solutions. Founded by Fapon Group and circular RNA pioneer Dr. Alex Wesselhoeft, MOTE is tackling one of the most fundamental bottlenecks in nucleic acid medicine: delivering RNA payloads to cells and tissues beyond the liver. The mobilize™ platform’s modular, non-covalent design—which avoids complex chemical conjugation—is engineered for manufacturability and scalability, critical components for commercial viability.

Preclinical data for the platform is already compelling. Company reports indicate an 80% reduction in liver uptake, a significant achievement that opens the door to treating systemic diseases. Furthermore, in non-human primate studies, a single low dose of its in vivo CAR-T candidate generated CAR+ T-cells in approximately 30% of CD8+ T-cells, leading to subsequent B-cell depletion. This is a powerful proof-of-concept for a technology that could transform treatments for intractable diseases like systemic lupus erythematosus, multiple myeloma, and even neurodegenerative disorders.

With MOTE actively raising a $40 million Series A to propel its programs toward the clinic, this is a clear signal to the market. The company is not just developing a product; it is building a delivery engine capable of carrying various genetic payloads to previously inaccessible tissues, a capability that will be highly sought after for partnerships and collaborations.

A Pipeline Primed for the Clinic

The strategic depth of Fapon Group is further evidenced by the rapid maturation of its broader pipeline. The B-cell franchise is not a distant dream; it is on the cusp of human trials. An investigator-initiated study for the in vivo CAR-T program, MTX001, is anticipated in the fourth quarter of this year, a remarkably fast timeline for such a novel modality. The tri-specific T-cell engager, FPE024, is targeting an Investigational New Drug (IND) filing in the first quarter of 2027.

Beyond B-cell depletion, the pipeline showcases a diversified portfolio targeting major unmet needs. This includes FP008, a first-in-class PD1×IL10M fusion protein for immuno-oncology, which is already in a Phase I study (NCT06990698) with key data expected this year. Another asset, FP002, is also in a Phase 1 study (NCT05982080) for advanced malignancies. Further preclinical assets, like a TL1A fusion protein for inflammatory bowel disease (FP012) and a CDH17-targeting T-cell engager for gastrointestinal cancers (FPE021), are entering IND-enabling studies, demonstrating a sustained R&D momentum.

This deliberate cadence of clinical progression, from early-stage innovation to Phase I readouts, reflects a mature development strategy. It provides a steady stream of potential value-inflection points and de-risks the overall enterprise by not relying on a single asset or platform. For a company that only entered the biopharma space in 2015, this level of pipeline maturity is a testament to an aggressive and well-funded strategy.

The Global Commerce of Innovation

Fapon Group’s presentation at BIO 2026 is as much a business development mission as it is a scientific showcase. The explicit call for flexible partnership models, including co-development and licensing, underscores a pragmatic understanding of the global biopharmaceutical ecosystem. Building cutting-edge platforms is capital-intensive, and bringing novel therapies to market requires global reach and specialized expertise.

By actively courting partners, Fapon and its affiliates are looking to accelerate development, share risk, and tap into the commercial infrastructure of established players. Fapon Group's history as a global provider of IVD raw materials to over 2,500 partners in 70 countries provides it with a unique global perspective and an existing network to leverage. This is not a nascent startup seeking its first deal; it is a strategic player executing a global expansion plan.

As the industry converges in San Diego, the dual-platform strategy presented by Fapon Biopharma and MOTE Therapeutics offers a compelling look at the future of therapeutic development. It is a future defined not by single magic bullets, but by integrated, multi-modal systems designed to attack complex diseases from multiple angles. For those navigating the intersection of technology and commerce, this is a strategy worth watching.